Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

(19)

(11)

EP 1 203 766 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	11.04.2012 Bulletin 2012/15

(45)	Mention of the grant of the patent:
	29.02.2012 Bulletin 2012/09

(21)	Application number: 01125494.3

(22)	Date of filing: 06.11.2001

(51)

International Patent Classification (IPC):

C07D 213/75^(2006.01)
C07D 221/04^(2006.01)
C07D 401/04^(2006.01)
C07D 403/12^(2006.01)
C07D 409/06^(2006.01)
C07D 409/14^(2006.01)
C07D 413/12^(2006.01)
C07D 471/04^(2006.01)
A61K 31/44^(2006.01)
A61K 31/4704^(2006.01)
A61P 35/00^(2006.01)

C07D 215/22^(2006.01)
C07D 221/16^(2006.01)
C07D 401/12^(2006.01)
C07D 405/12^(2006.01)
C07D 409/12^(2006.01)
C07D 413/06^(2006.01)
C07D 417/06^(2006.01)
A61K 31/505^(2006.01)
A61K 31/50^(2006.01)
A61P 29/00^(2006.01)

(54)	Carboxylic acid derivatives that inhibit the binding of integrins to their receptors Carbonsäurederivate, die die Bindung von Integrinen an ihre Rezeptoren hemmen Dérivés d'acides carboxyliques inhibant la liaison des intégrines à leurs récepteurs

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30)

Priority:

06.11.2000 US 707068
09.10.2001 US 973142

(43)	Date of publication of application:
	08.05.2002 Bulletin 2002/19

(73)	Proprietor: ENCYSIVE PHARMACEUTICALS, INC.
	New York, NY 10017 (US)

(72)	Inventors:
	Biediger, Ronald J. Houston, TX 77095 (US) Chen, Qi Pearland, TX 77584 (US) Holland, George W. Houston, Texas 77007 (US) Kassir, Jamal M. Stafford, Texas 77477 (US) Li, Wen Houston, TX 77057 (US) Market, Robert V. Pearland, TX 77581 (US) Scott, Ian L. Delanson, NY 12053 (US) Wu, Chengde Pearland, TX 77584 (US) Decker, Radford E. Houston, TX 77018 (US) Li, Jian Houston, TX 77382 (US)

(74)	Representative: Weber, Martin et al
	Jones Day Prinzregentenstraße 11 80538 München 80538 München (DE)

(56)

References cited: :

EP-A- 0 355 819
WO-A-00/67746
WO-A-01/46190
WO-A-96/22966
DE-A- 2 614 189
US-A- 5 721 366

EP-A- 0 512 831
WO-A-00/68188
WO-A-91/13862
WO-A-99/52493
US-A- 5 484 946

L. ISMAILI ET AL: "Synthesis of New Pyrazolo(4,3-c)quinoline-3-one Derivatives and some Oxazolo(4,5-c)quinoline-2,4-diones" JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 36, no. 3, 1999, pages 719-722, XP002298894
J.J. PANOUSE ET AL: "Relations structures-activités des immunomodulateurs. Apport de la modélisation moléculaire" ANNALES PHARMACEUTIQUES FRANCAISES, vol. 58, no. 5, 2000, pages 291-302, XP008036024

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).